5 Key Takeaways

• 1

  China's National Medical Products Administration approved satricabtagene autoleucel, the first CAR T-cell therapy for solid tumors.

• 2

  Satricabtagene autoleucel targets Claudin18.2 and is approved for advanced gastric or gastroesophageal junction adenocarcinoma.

• 3

  Approval is based on the phase 2 CT041-ST-01 trial, showing progression-free and overall survival benefits for satricabtagene autoleucel.

• 4

  Wearable devices may help detect cytokine release syndrome earlier in CAR T-cell therapy patients, according to a pilot study.

• 5

  A liver-targeted gene therapy showed promise in mice for treating arthrogryposis, renal dysfunction, and cholestasis syndrome.